Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease

Journal of Cystic Fibrosis

Volumn 16, Issue 3, 2017, Pages 388-391

  Hubert, Dominique ^a,b   Chiron, Raphaël ^c   Camara, Boubou ^d   Grenet, Dominique ^e   Prévotat, Anne ^f   Bassinet, Laurence ^g   Dominique, Stéphane ^h   Rault, Gilles ⁱ   Macey, Julie ^j   Honoré, Isabelle ^a,b   Kanaan, Reem ^a,b   Leroy, Sylvie ^k   Desmazes Dufeu, Nadine ^l   Burgel, Pierre Régis ^a,b  

^a AP HP ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e FOCH HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^h HÔPITAL CHARLES NICOLLE   (France)

ⁱ CRCM Centre de Perharidy   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k UNIVERSITÉ CÔTE D'AZUR   (France)

^l HÔPITAL NORD   (France)

more..

Author keywords

CFTR correctors; Cystic fibrosis; Lumacaftor ivacaftor

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR PLUS LUMACAFTOR; PYRROLE; 1,3 BENZODIOXOLE DERIVATIVE; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; LUMACAFTOR, IVACAFTOR DRUG COMBINATION; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ANTIFUNGAL THERAPY; ARTICLE; BODY MASS; BREAST TENSION; BREATHING DISORDER; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATION; NAUSEA; OBSERVATIONAL STUDY; PRESCRIPTION; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; TREATMENT DURATION; VOMITING; CLINICAL TRIAL; DRUG COMBINATION; DRUG MONITORING; FRANCE; GENETICS; PROCEDURES; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; FRANCE; HUMANS; MALE; MEMBRANE TRANSPORT MODULATORS; MUTATION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUINOLONES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; WITHHOLDING TREATMENT;

EID: 85015033159     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2017.03.003     Document Type: Article

References (7)

1. [1] Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., et al. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373 (2015), 220–231.
2. [2] Elborn, J.S., Ramsey, B.W., Boyle, M.P., Konstan, M.W., Huang, X., Marigowda, G., et al. For the VX-809 TRAFFIC and TRANSPORT study groups. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med 4 (2016), 617–626.
3. [3] Jennings, M.T., Dezube, R., Hong, G., West, N.E., Braun, A., Merlo, C., et al. Lumacaftor/ivacaftor: an observational study of outcomes and tolerances in patients with cystic fibrosis. Am J Respir Crit Care Med, 193, 2016, A7790 [abstract].
4. [4] Anstead, M., Tupayachi, G., Murphy, D., Autry, E., Bulkley, V., Kuhn, R., Lumacaftor/ivacaftor: real world experience in a CF center. Pediatr Pulmonol, 51(S45), 2016, 302 [abstract 290].
5. [5] Wang, J., Lester, M.K., Benitez, D., Rao, A., Beringer, P., Use of in-clinic challenge dosing to assess safety and tolerability of lumacaftor/ivacaftor. Pediatr Pulmonol 51:S45 (2016), 363–364 [abstract 448].
6. [6] Konstan, M., McKone, E.F., Moss, R.B., Marigowda, G., Tian, S., Waltz, D., et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation(PROGRESS): a phase 3, extension study. Lancet Respir Med 5:2 (2017), 107–118.
7. [7] Marigowda, G., Liu, F., Waltz, D., Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy. J Cyst Fibros 16:2 (2017), 246–249.